DV
Dividend Vision

GLUE — Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. (GLUE)

Total return is -26.8% over the past 5.1 years, 122.2 points behind SPY at 95.4%. Its deepest 1-year drawdown was 41.8%.

This is a single-stock equity position in Monte Rosa Therapeutics, Inc., a biopharmaceutical company, rather than a diversified ETF. The holding pays no distributions and carries no dividend yield, making it unsuitable for income-focused strategies. This security appeals primarily to growth-oriented investors seeking exposure to the therapeutic development sector, though it lacks the diversification and passive management structure typical of ETFs.

GLUE key facts

Asset type
Stock
Asset class
Equity
Inception date
06/24/2021
Distribution frequency
None
Last close
$15.50
Market cap
$1,322,357,760
Average volume
509501.0
Beta
1.527
Payout ratio
0.0
Forward P/E
10.8578
EPS
$-1.71